SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Andersson B.) srt2:(1990-1999)"

Search: WFRF:(Andersson B.) > (1990-1999)

  • Result 1-10 of 470
Sort/group result
   
EnumerationReferenceCoverFind
1.
  •  
2.
  •  
3.
  •  
4.
  •  
5.
  • Clarke, Robert, et al. (author)
  • Lowering blood homocysteine with folic acid based supplements : Meta-analysis of randomised trials
  • 1998
  • In: British Medical Journal. - : BMJ. - 0959-8146. ; 316:7135, s. 894-898
  • Research review (peer-reviewed)abstract
    • Objective: To determine the size of reduction in homocysteine concentrations produced by dietary supplementation with folic acid and with vitamins B-12 or B-6. Design: Meta-analysis of randomised controlled trials that assessed the effects of folic acid based supplements on blood homocysteine concentration. Multivariate regression analysis was used to determine the effects on homocysteine concentrations of different doses of folic acid and of the addition of vitamin B-12 or B-6. Subjects: Individual data on 1114 people included in 12 trials. Findings: The proportional and absolute reductions in blood homocysteine produced by folic acid supplements were greater at higher pretreatment blood homocysteine concentrations (P < 0.001) and at lower pretreatment blood folate concentrations (P < 0.001). After standardisation to pretreatment blood concentrations of homocysteine of 12 μmol/l and of folate of 12 nmol/l (approximate average concentrations for Western populations), dietary folic acid reduced blood homocysteine concentrations by 25% (95% confidence interval 23% to 28%; P < 0.001), with similar effects in the range of 0.5-5 mg folic acid daily. Vitamin B-12 (mean 0.5 mg daily) produced an additional 7% (3% to 10%) reduction in blood homocysteine. Vitamin B-6 (mean 16.5 mg daily) did not have a significant additional effect. Conclusions: Typically in Western populations, daily supplementation with both 0.5-5 mg folic acid and about 0.5 mg vitamin B-12 would be expected to reduce blood homocysteine concentrations by about a quarter to a third (for example, from about 12 μmol/l to 8-9 μmol/l). Large scale randomised trials of such regimens in high risk populations are now needed to determine whether lowering blood homocysteine concentrations reduces the risk of vascular disease.
  •  
6.
  •  
7.
  •  
8.
  • Tropé, C, et al. (author)
  • Doxorubicin-melphalan with and without cisplatin in advanced ovarian cancer--ten-year survival results from a prospective randomized study by the Swedish Cooperative Ovarian Cancer Study Group
  • 1996
  • In: Acta oncologica (Stockholm, Sweden). - : Informa UK Limited. - 0284-186X .- 1651-226X. ; 35 Suppl 8, s. 18-109
  • Journal article (peer-reviewed)abstract
    • In a controlled prospective randomized study the regimen doxorubicin (A) 40 mg/m2 + melphalan (M) 0.4 mg/kg was compared with A + M + cisplatin (C) 50 mg/m2 given every four weeks in advanced ovarian cancer, FIGO stage III or IV and with serous or anaplastic histology. From 1981 to 1983, 300 patients entered the study and 295 patients were evaluable for response, toxicity and long-term survival. All patients were followed for at least 10 years. The majority of patients had large residual tumours >2 cm. Patients treated with MAC had a higher response rate compared with patients treated with MA (76% vs. 50%, p < 0.01) and treatment with MAC resulted in significantly more pathological complete responders than MA. There was a significant difference in median duration of response (19 months vs. 13 months, p < 0.006) and in median survival time (26 months vs. 19 months, p = 0.05). After 5- and 10 years a significant difference in progression-free and overall survival was found. The independent prognostic factors in this study were residual tumour after primary surgery, treatment with MAC, tumour grade, ascites, and stage. Objective and subjective side effects were significantly worse with MAC, although tolerable. In conclusion, this study shows that incorporating C into MA improves the duration of progression-free survival and overall survival in women with incompletely resected Stage III or Stage IV ovarian epithelial cancer. A 5- and 10-year survival of 25% and 18%, respectively, is impressive.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-10 of 470
Type of publication
journal article (391)
conference paper (37)
other publication (14)
reports (12)
book chapter (9)
review (4)
show more...
research review (2)
doctoral thesis (1)
show less...
Type of content
peer-reviewed (343)
other academic/artistic (127)
Author/Editor
Andersson, B. (56)
Andersson, P (53)
Adye, T. (50)
Andreazza, A. (50)
Amaldi, U. (50)
Amato, S. (50)
show more...
Antilogus, P. (50)
Allport, PP (50)
Apel, WD (50)
Alekseev, GD (50)
Almehed, S (50)
Asman, B. (49)
Abreu, P. (49)
Alemany, R (48)
Adam, W. (47)
Arnoud, Y. (45)
Augustin, JE (40)
Andersson, J (40)
Adzic, P. (39)
Langstrom, B (34)
Augustinus, A. (33)
Andersson, K (31)
Baillon, P. (30)
Bambade, P. (30)
Andersson, G (26)
Andersson, A (26)
Anassontzis, EG (26)
Barao, F (26)
Ajinenko, I (25)
Andringa, S. (24)
Allmendinger, T. (20)
Andersson, K E (18)
Andersson, M (18)
Alderweireld, T. (16)
Albrecht, Z (15)
Bardin, DY (15)
Andersson, Kerstin (15)
Roos, B. O. (15)
Barbi, M. (14)
Andersson, Y. (14)
Alm, P (14)
Andersson, U (12)
Persson, Katarina (12)
Andersson, S (11)
Melin, L (11)
Lilja, A (11)
Andersson, H. (10)
Hartvig, P (10)
Scott, B (10)
GROSS, J (10)
show less...
University
Uppsala University (171)
Karolinska Institutet (146)
Lund University (41)
Linnaeus University (22)
University of Gothenburg (18)
Karlstad University (18)
show more...
Linköping University (17)
Luleå University of Technology (14)
Chalmers University of Technology (10)
Royal Institute of Technology (9)
Örebro University (7)
RISE (6)
Umeå University (5)
Stockholm University (5)
Högskolan Dalarna (4)
Jönköping University (3)
Swedish National Defence College (1)
show less...
Language
English (455)
Swedish (14)
Undefined language (1)
Research subject (UKÄ/SCB)
Medical and Health Sciences (45)
Natural sciences (44)
Engineering and Technology (26)
Social Sciences (4)
Agricultural Sciences (3)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view